Lyra Therapeutics Return on Equity

Lyra Therapeutics (LYRA) currently reports a ROE of 269.84%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Lyra Therapeutics's ROE history and peer comparisons.

Lyra Therapeutics's ROE of 269.84% is higher than the Healthcare sector average of 21.67%. That is roughly 1145.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lyra Therapeutics's current 269.84% should be judged against Healthcare norms (sector average: 21.67%) and against LYRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 269.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.

Lyra Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 269.84% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYRA with unrelated industries.